Equities Analysts Offer Predictions for Qiagen Q1 Earnings

Qiagen (NYSE:QGEN) – Equities research analysts at William Blair cut their Q1 2025 earnings estimates for Qiagen in a note issued to investors on Friday, February 7th. William Blair analyst A. Brackmann now anticipates that the company will post earnings per share of $0.49 for the quarter, down from their previous forecast of $0.50. The consensus estimate for Qiagen’s current full-year earnings is $2.28 per share. William Blair also issued estimates for Qiagen’s Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.58 EPS, Q4 2025 earnings at $0.61 EPS, FY2025 earnings at $2.26 EPS, Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.61 EPS, Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.66 EPS and FY2026 earnings at $2.43 EPS.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.97%.

QGEN has been the topic of several other research reports. Morgan Stanley reissued an “equal weight” rating and issued a $46.67 target price (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $47.64 target price on the stock. in a report on Thursday, October 17th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. UBS Group dropped their target price on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a report on Friday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $52.50 target price (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Qiagen has an average rating of “Hold” and an average target price of $48.78.

Qiagen Trading Down 3.0 %

Shares of QGEN opened at $40.10 on Monday. Qiagen has a twelve month low of $39.63 and a twelve month high of $49.30. The company has a market cap of $8.90 billion, a P/E ratio of 111.66, a P/E/G ratio of 3.29 and a beta of 0.36. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The company’s fifty day simple moving average is $43.74 and its 200-day simple moving average is $43.28.

Institutional Investors Weigh In On Qiagen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in Qiagen by 3.9% during the 3rd quarter. State Street Corp now owns 2,380,008 shares of the company’s stock worth $108,457,000 after purchasing an additional 90,181 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Qiagen by 5.0% during the 3rd quarter. Jennison Associates LLC now owns 1,426,392 shares of the company’s stock valued at $65,001,000 after acquiring an additional 68,415 shares during the last quarter. XTX Topco Ltd boosted its position in shares of Qiagen by 129.3% during the 3rd quarter. XTX Topco Ltd now owns 20,192 shares of the company’s stock valued at $920,000 after acquiring an additional 11,385 shares during the last quarter. Sanctuary Advisors LLC boosted its position in shares of Qiagen by 24.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock valued at $834,000 after acquiring an additional 3,878 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Qiagen by 36.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock valued at $73,096,000 after acquiring an additional 424,937 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.